Compare HSBC Holdings plc (HSBC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Summit Therapeutics Inc — how do they compare? HSBC Holdings plc trades at $92.98 (market cap $311.92B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: HSBC Holdings plc is far larger — about 22.8× Summit Therapeutics Inc's market cap, and HSBC Holdings plc pays a 4.05% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and Summit Therapeutics Inc for 16 Days on average.
| HSBC | SMMT | |
|---|---|---|
Market Cap | $311.92B | $13.71B |
Volume | 3,546,658 | 6,173,057 |
Sector | Financials | Health |
52-Week High | $107.86 | $26.38 |
52-Week Low | $65.67 | $12.43 |
Typical Hold Time | 36 Days | 16 Days |
Enterprise Value | $222.19B | $13.04B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.98, down 0.78% today, with a bearish technical signal from moving averages and oscillators. The stock shows solid fundamentals with a P/E of 13.23, net income margin of 34.54%, and ROE of 12.44%. Recent earnings were mixed, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. News highlights strategic moves like expanding in India equity broking and enhancing U.S. Premier services, while the CFO plans to step down in 2027.
The outlook is cautiously optimistic given strong profitability and growth initiatives, but risks include execution challenges from business restructuring and macroeconomic headwinds. Analysts are divided with 38.1% buy ratings, suggesting potential upside if earnings momentum improves, though bearish technicals warrant monitoring near support at $91.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
